[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336512-105":59,"doc-detail-336512-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","phase-ii-basket-trial-of-dual-anti-ctla-4-and-anti-pd-1-blockade-in-rare-tumors-dart-adrenocortical-carcinoma-cohort","Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) - adrenocortical carcinoma cohort","","Objectives Multiple common cancers benefit from immunotherapy, yet efficacy in rare tumors remains less defined. This report presents results for the adrenocortical carcinoma cohort from the NCI/SWOG S1609 DART study evaluating dual blockade with ipilimumab plus nivolumab. Design/setting A prospective phase 2 basket trial across multiple rare cohorts at over 1,000 National Clinical Trial Network sites. Results included ORR 14% with RECIST V1.1 and immune response endpoints, alongside reported PFS, OS, and safety outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/phase-ii-basket-trial-of-dual-anti-ctla-4-and-anti-pd-1-blockade-in-rare-tumors-dart-adrenocortical-carcinoma-cohort/336512/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/phase-ii-basket-trial-of-dual-anti-ctla-4-and-anti-pd-1-blockade-in-rare-tumors-dart-adrenocortical-carcinoma-cohort/336512.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What study is reported for adrenocortical carcinoma in the DART program?","Question",{"text":113,"@type":114},"The document reports the results of the adrenocortical carcinoma cohort from the NCI/SWOG S1609 Phase II basket trial evaluating dual Anti-CTLA-4 and Anti-PD-1 blockade using ipilimumab plus nivolumab.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many eligible patients were registered and what were the key demographics?",{"text":118,"@type":114},"Twenty-one eligible patients were registered, with a median age of 53 years (range 26–69) and 16 patients (76%) being women.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the primary efficacy and immune-related outcomes?",{"text":122,"@type":114},"The primary endpoint was overall response rate (ORR) assessed by RECIST V1.1, and immune-related outcomes included immune ORR (iORR), immune clinical benefit rate (iCBR), and immune progression-free survival (iPFS).","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336512,1790193130,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Open access Short report  \n Phase II basket trial of Dual Anti  \nCTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609:  \nadrenocortical carcinoma cohort  \nSandip P Patel  ,1 Megan Othus,2 Young Kwang Chae  ,3 Tridu Huynh,4 Benjamin Tan,5 Timothy Kuzel,6 Christine McLeod,7 Gabby Lopez,8 Helen X Chen,9 Elad Sharon,10 Howard Streicher,11 Christopher W Ryan,12 Charles Blanke,12 Razelle Kurzrock13  \nTo cite: Patel SP, Othus M, Chae YK, et al. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort. Journal for ImmunoTherapy of Cancer 2024;12:e009074 . doi:10 . 1136/ jitc-2024-009074  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-009074](jitc-2024-009074)) .  \nSPP and YKC contributed equally.  \nAccepted 09 July 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Sandip P Patel; [spatel@ucsd.edu](spatel@ucsd.edu)  \nDr Young Kwang Chae; [chaelabmeeting@gmail.com](chaelabmeeting@gmail.com)  \nRazelle Kurzrock; [rkurzrock@mcw.edu](rkurzrock@mcw.edu)  \nABSTRACT  \nObjectives Multiple common cancers benefit from immunotherapy; however, less is known about efficacy in rare tumors. We report the results of the adrenocortical carcinoma cohort of NCI/SWOG S1609 Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.  \nDesign/setting A prospective, phase 2 clinical trial of ipilimumab plus nivolumab was conducted by the SWOG Early Therapeutics and Rare Cancers Committee for multiple rare tumor cohorts across >1,000 National Clinical Trial Network sites.  \nParticipants 21 eligible patients were registered. Median age was 53 years (range 26–69); 16 (76%) were women. Interventions Ipilimumab 1 mg/kg intravenously every 6 weeks with nivolumab 240 mg intravenously every  \n2 weeks was administered until disease progression, symptomatic deterioration, treatment delay for any reason >56 days, unacceptable or immune-related toxicity withinability to decrease prednisone to \u003C10 mg daily, or per patient request.  \nMain outcome measures The primary endpoint was the overall response rate (ORR) (RECIST V.1.1). Secondary endpoints include clinical benefit rate (CBR) (includes stable disease (SD)>6 months), progression-free survival (PFS), overall survival (OS), and toxicity. Immune-related outcomes included immune ORR (iORR), immune CBR (iCBR), and immune PFS (iPFS) . A two-stage design was used assuming: null=5% alternative=30%, n=6 in the first stage, 16 max, one-sided alpha=13% .  \nResults The median number of prior therapy lines was 2 (range: 1–9) . 3 of 21 patients attained confirmed partial response (PR) (ORR=14%) . In addition, one patient had an unconfirmed PR; one, stable disease (SD)>6 months; one, immune-related RECIST (iRECIST) PR (iPR); and one patient attained iSD>6 months: clinical benefit rate (response or SD>6 months)=5/21 (24%), iORR=4/21 (19%), iCBR=7/21 (33%) . The 6-month PFS was 24%; 6-month iPFS, 33% . The PFS for patients (N=7) with iRECIST clinical benefit were 57, 52, 18, 15, 13, 7, and 7 months. The 6-month OS was 76%; the median OS, was 15.8 months. The most common toxicities were fatigue (62%) and rash (38%), and the most common grade 3/4 immune-related adverse events were hepatic dysfunction (9 .5%) and adrenal insufficiency (9 .5%) . Treatment-related adverse events  \nleading to discontinuation of therapy in four patients (21%) . There were no grade 5 adverse events. Conclusions Ipilimumab plus nivolumab is active in refractory metastatic adrenocortical cancer meeting the primary endpoint of the study, with a 19% iORR and 33% iCBR (includes SD/iSD>6 months) and with the longest PFS/iPFS of 52 and 57 months.  \nTrial registration numbe","cbCaihpbV6J7Imaz","https://ap.wps.com/l/cbCaihpbV6J7Imaz","pdf",1217574,"English","# Abstract\n## Objectives\n## Design/setting\n## Participants and interventions\n## Main outcome measures\n## Results\n## Conclusions\n# Introduction\n# Patients and methods","[{\"question\":\"What study is reported for adrenocortical carcinoma in the DART program?\",\"answer\":\"The document reports the results of the adrenocortical carcinoma cohort from the NCI/SWOG S1609 Phase II basket trial evaluating dual Anti-CTLA-4 and Anti-PD-1 blockade using ipilimumab plus nivolumab.\"},{\"question\":\"How many eligible patients were registered and what were the key demographics?\",\"answer\":\"Twenty-one eligible patients were registered, with a median age of 53 years (range 26–69) and 16 patients (76%) being women.\"},{\"question\":\"What were the primary efficacy and immune-related outcomes?\",\"answer\":\"The primary endpoint was overall response rate (ORR) assessed by RECIST V1.1, and immune-related outcomes included immune ORR (iORR), immune clinical benefit rate (iCBR), and immune progression-free survival (iPFS).\"}]","Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) - adrenocortical carcinoma cohort | PDF",1790015391,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d3c4039fbfe1b6213d3997d538e37c4.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ee89361d19a8a22b8ea2c833b7fca47.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/386a7626368e938a746bf47eb267e790.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ef96af14347700ea4dcab3f7fdf7bf6.webp",980,1306]